Publications in collaboration with researchers from Hospital de Fuenlabrada (18)

2022

  1. Defining a Standard Set of Patient-Reported Outcomes for Patients With Advanced Ovarian Cancer

    Frontiers in Oncology, Vol. 12

  2. Phosphoproteomic analysis of neoadjuvant breast cancer suggests that increased sensitivity to paclitaxel is driven by CDK4 and filamin A

    Nature Communications, Vol. 13, Núm. 1

2020

  1. High-dose neoadjuvant chemoradiotherapy versus chemotherapy alone followed by surgery in potentially-resectable stage IIIA-N2 NSCLC. A multi-institutional retrospective study by the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society)

    Reports of Practical Oncology and Radiotherapy, Vol. 25, Núm. 3, pp. 447-455

  2. Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial

    Breast Cancer Research, Vol. 22, Núm. 1

  3. Palbociclib combined with endocrine therapy in heavily pretreated HR+/HER2- advanced breast cancer patients: Results from the compassionate use program in Spain (PALBOCOMP)

    Breast, Vol. 54, pp. 286-292

  4. Phase III study to evaluate patient’s preference of subcutaneous versus intravenous trastuzumab in HER2-positive metastatic breast cancer patients: Results from the ChangHER study (GEICAM/2012-07)

    European Journal of Cancer Care, Vol. 29, Núm. 4

2019

  1. Nintedanib plus letrozole in early breast cancer: A phase 0/I pharmacodynamic, pharmacokinetic, and safety clinical trial of combined FGFR1 and aromatase inhibition

    Breast Cancer Research, Vol. 21, Núm. 1

  2. Prognostic factors in neoadjuvant treatment followed by surgery in stage IIIA-N2 non-small cell lung cancer: a multi-institutional study by the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society)

    Clinical and Translational Oncology, Vol. 21, Núm. 6, pp. 735-744

  3. Quantitative assessment of interstitial lung disease in Sjögren’s syndrome

    PLoS ONE, Vol. 14, Núm. 11

  4. Systemic manifestations of primary Sjögren's syndrome out of the ESSDAI classification: Prevalence and clinical relevance in a large international, multi-ethnic cohort of patients

    Clinical and Experimental Rheumatology, Vol. 37, pp. S97-S106

  5. The Big Data Sjögren consortium: A project for a new data science era

    Clinical and Experimental Rheumatology, Vol. 37, pp. S19-S23

2018

  1. Addition of durvalumab (Dur) upon progression to bevacizumab (Bev) maintenance in advanced HER2-negative (HERNEG) breast cancer (BC): Safety, efficacy and biomarkers

    Annals of Oncology, Vol. 29, pp. ix24

  2. How immunological profile drives clinical phenotype of primary Sjögren's syndrome at diagnosis: Analysis of 10,500 patients (Sjögren Big Data Project)

    Clinical and Experimental Rheumatology, Vol. 36, pp. S102-S111

  3. Importance of 68Ga-PSMA PET/CT in hospital practice. View of the radiation oncologist

    Revista Espanola de Medicina Nuclear e Imagen Molecular, Vol. 37, Núm. 5, pp. 302-314

  4. Neoadjuvant treatment followed by surgery versus definitive chemoradiation in stage IIIA-N2 non-small-cell lung cancer: A multi-institutional study by the oncologic group for the study of lung cancer (Spanish Radiation Oncology Society)

    Lung Cancer, Vol. 118, pp. 119-127

  5. Severe, life-threatening phenotype of primary Sjögren's syndrome: Clinical characterisation and outcomes in 1580 patients (the GEAS-SS Registry)

    Clinical and Experimental Rheumatology, Vol. 36, pp. S121-S129

2017

  1. Characterization and risk estimate of cancer in patients with primary Sjögren syndrome

    Journal of Hematology and Oncology, Vol. 10, Núm. 1

  2. Magnetic resonance imaging for prostate cancer before radical and salvage radiotherapy: What radiation oncologists need to know

    World Journal of Clinical Oncology, Vol. 8, Núm. 4, pp. 305-319